Drug intelligence / Profile preview

gushen shetuo decoction

Development stage: Preclinical
Administration: Oral

Overview

Gushen Shetuo Decoction is a Traditional Chinese Medicine (TCM) herbal formula primarily investigated for the treatment of Parkinson's disease, specifically targeting non-motor symptoms like drooling (sialorrhea). In clinical and preclinical studies, it has demonstrated the ability to reduce drooling severity and frequency, improve motor complications, and protect the substantia nigra and striatum from pathological damage. Its mechanism of action is associated with the inhibition of the endoplasmic reticulum (ER) stress pathway, evidenced by the downregulation of PERK, ATF4, and CHOP expression in brain tissues.

Other names: Gushen Shetuo Tang固肾摄唾汤

Targets

ATF4 (Activating transcription factor 4)DDIT3 (DNA damage-inducible transcript 3 protein)EIF2AK3 (Pkr-like endoplasmic reticulum kinase)

Beyond the preview

Go deeper on gushen shetuo decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gushen shetuo decoction.

Explore the full profile